Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Seidman

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|June 21, 1995
Pruritus caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressantsR J Freilich, A D Seidman
Seminars in Oncology|December 1, 1991
The evolving role of chemotherapy for muscle infiltrating bladder cancerA D Seidman, H I Scher
Oncology (Williston Park, N.Y.)|June 5, 1999
Update on the management of advanced breast cancerM Fornier, P Munster, A D Seidman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2A D Seidman, S Barrett, S Canezo
International Journal of Clinical & Laboratory Research|January 1, 1994
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activityR Foa, L Norton, A D Seidman
Seminars in Oncology|August 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapyA D Seidman, C A Hudis, L Norton
Seminars in Oncology|March 10, 2001
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancerM Fornier, F J Esteva, A D Seidman
Breast Cancer Research and Treatment|May 12, 2010
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancerC G Murphy, M Khasraw, A D Seidman
Cancer|July 15, 1995
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxelR J Freilich, A D Seidman, L M DeAngelis
Cancer|February 1, 1993
Immune-mediated thrombocytopenia secondary to suraminA D Seidman, M Schwartz, L Reich, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|June 21, 1995
Pruritus caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressantsR J Freilich, A D Seidman
Seminars in Oncology|December 1, 1991
The evolving role of chemotherapy for muscle infiltrating bladder cancerA D Seidman, H I Scher
Oncology (Williston Park, N.Y.)|June 5, 1999
Update on the management of advanced breast cancerM Fornier, P Munster, A D Seidman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2A D Seidman, S Barrett, S Canezo
International Journal of Clinical & Laboratory Research|January 1, 1994
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activityR Foa, L Norton, A D Seidman
Seminars in Oncology|August 1, 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapyA D Seidman, C A Hudis, L Norton
Seminars in Oncology|March 10, 2001
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancerM Fornier, F J Esteva, A D Seidman
Breast Cancer Research and Treatment|May 12, 2010
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancerC G Murphy, M Khasraw, A D Seidman
Cancer|July 15, 1995
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxelR J Freilich, A D Seidman, L M DeAngelis
Cancer|February 1, 1993
Immune-mediated thrombocytopenia secondary to suraminA D Seidman, M Schwartz, L Reich, et al.
Pageof 6